Most Helicobacter pylori strains are susceptible to tetracycline, an antibiotic commonly used for the eradication of H. pylori. However, an increase in incidence of tetracycline resistance in H. pylori has recently been reported. Here the mechanism of tetracycline resistance of the first Dutch tetracycline-resistant (Tet r ) H. pylori isolate (strain 181) is investigated. Twelve genes were selected from the genome sequences of H. pylori strains 26695 and J99 as potential candidate genes, based on their homology with tetracycline resistance genes in other bacteria. With the exception of the two 16S rRNA genes, none of the other putative tetracycline resistance genes was able to transfer tetracycline resistance. Helicobacter pylori is a spiral-shaped, gram-negative bacterium that causes chronic infections in the gastric mucosa (6). This infection will persist for life, unless treated with antibiotics. Cure of H. pylori infection results in ulcer healing and may reduce the risk of gastric cancer and gastric lymphoma (22, 28) . The highest cure rates have been obtained with antimicrobial treatments that include two or more antimicrobial drugs, a bismuth component, and/or a proton pump inhibitor (14, 25). For the treatment of H. pylori infections, tetracycline-based triple or quadruple therapies are often used as a second-line treatment (7, 9, 17) . Until the end of the last century only a few reports were published on spontaneous tetracycline resistance (18; P. D. Midolo, M. G. Korman, J. D. Turnidge, and J. R. Lambert, Letter, Lancet 347:1194-1195, 1996), and it was generally accepted that tetracycline resistance (MIC Ն 4 g/ml) in H. pylori is very rare (5, 12). However, in the last 2 years an increase in the incidence of tetracycline resistance in H. pylori has been reported (2, 11, 13, 20, 30) .
Helicobacter pylori is a spiral-shaped, gram-negative bacterium that causes chronic infections in the gastric mucosa (6) . This infection will persist for life, unless treated with antibiotics. Cure of H. pylori infection results in ulcer healing and may reduce the risk of gastric cancer and gastric lymphoma (22, 28) . The highest cure rates have been obtained with antimicrobial treatments that include two or more antimicrobial drugs, a bismuth component, and/or a proton pump inhibitor (14, 25) . For the treatment of H. pylori infections, tetracycline-based triple or quadruple therapies are often used as a second-line treatment (7, 9, 17) . Until the end of the last century only a few reports were published on spontaneous tetracycline resistance (18; P. D. Midolo, M. G. Korman, J. D. Turnidge, and J. R. Lambert, Letter, Lancet 347:1194-1195, 1996), and it was generally accepted that tetracycline resistance (MIC Ն 4 g/ml) in H. pylori is very rare (5, 12) . However, in the last 2 years an increase in the incidence of tetracycline resistance in H. pylori has been reported (2, 11, 13, 20, 30) .
Tetracycline inhibits the protein synthesis by binding to the 30S ribosomal subunit (3, 19) . In most bacteria resistance to tetracycline is due to an energy-dependent efflux of tetracycline-cation complexes across the cell membrane by membrane-associated efflux proteins. Export of tetracycline complexes out of the cell reduces the intracellular drug concentration and protects the ribosomes from tetracycline (4) . Overexpression of the efflux genes confers tetracycline resistance, while the sensitivity to tetracycline increases by deletions in these genes. The second common mechanism of resistance is mediated through ribosomal protection proteins. These cytoplasmic proteins confer tetracycline resistance either by a reduction of the affinity of ribosomes for tetracycline or by releasing the bound antibiotic from the ribosome. The ribosomal protection proteins, such as TetM, TetO, and TetS, show homology with the elongation factors EF-G and EF-Tu (Table 1 ) (4). Beside these two most common tetracycline resistance mechanisms, two other mechanisms have been described. One is based on enzymatic inactivation of tetracycline by the product of TetX in the presence of oxygen and NADPH, and the other originates from mutations in the 16S rRNA genes that affect the binding site of tetracycline (4, 21, 24) .
We recently isolated a tetracycline-resistant (Tet r ) H. pylori isolate (strain 181), from a 72-year-old male dyspeptic patient. Here we describe the molecular mechanism of tetracyclineresistance in this strain. To achieve this, 12 genes were selected from the published H. pylori genomes (1, 23) as potential candidates, based on their homology with tetracycline resistance genes in other bacteria (Table 1) . These putative tetracycline resistance genes were amplified from the genome of the Tet r strain 181 and used for genetic transformation of the tetracycline-sensitive (Tet s ) strain 26695 in order to identify the changes responsible for tetracycline resistance. (8) . Inocula were prepared from a fresh H. pylori culture grown routinely for 2 days on Dent plates. Columbia agar plates containing 7% lysed horse blood, but no Dent supplement, were inoculated with approximately 2 ϫ 10 8 CFU in 20 l of 0.9% NaCl, the plates were dried for 3 to 4 min, and then the E-test strips were applied to the agar surface. The plates were incubated at 37°C under microaerobic conditions, and 3 days later the MIC was determined by the intercept of the zone of inhibition with the graded E-test strip. By this method the susceptibility was determined for tetracycline, doxycycline, minocycline, amoxicillin, clarithromycin, and metronidazole. The isolates were considered resistant when the MICs of tetracycline, doxycycline, and minocycline were Ն4 g/ml and when those of amoxicillin, clarithromycin, and metronidazole were Ն8, Ն2, and Ն8g/ml, respectively (5, 13).
MATERIALS AND METHODS

Bacterial
Natural transformation of H. pylori. Bacteria were transformed with ϳ1 g of genomic DNA or ϳ250 ng of PCR-amplified gene products from strain 181, as described previously (27) . Tet r transformants were selected on Dent plates containing tetracycline (2 g/ml; Sigma Aldrich Chemie, Zwijndrecht, The Netherlands). As controls, bacteria were transformed with either genomic DNA of the 
RESULTS
Determination of the MICs of various antibiotics.
MICs of the four antibiotics commonly used in anti-H. pylori therapy, as well as those of two antibiotics that belong to the tetracycline family, were determined by E-test for the Tet r H. pylori strain 181 and the H. pylori reference strain 26695 ( Table 2 ). The MIC of tetracycline for strain 181 was 8 g/ml (susceptibility breakpoint Ն 4 g/ml), while the MIC for strain 26695 was 0.19 g/ml. The MICs of the two other tetracyclines, doxycycline and minocycline, were also significantly higher for strain 181 than for strain 26695. For the three other routinely used antibiotics (amoxicillin, clarithromycin, and metronidazole) the MICs varied between Ͻ0.016 and 0.064 g/ml and did not differ significantly between strains 181 and 26695.
Transfer of tetracycline resistance by natural transformation. Transformation of H. pylori strain 26695 (MIC, 0.19 g/ ml) with genomic DNA of strain 181 (MIC, 8 g/ml) resulted in Tet r colonies with a transformation frequency of 6 ϫ 10 Ϫ5 . The MIC of tetracycline for the 10 randomly selected Tet r transformants (obtained from three independent transformation experiments), determined by E-test was 8 g/ml (Table 2) , which is identical to that for the Tet r H. pylori strain 181. The Tet r transformants also displayed an increase of MIC of the tetracycline derivatives, doxycycline and minocycline (Table 2) .
Transformation with PCR products of putative tetracycline (Fig. 1) . Three Tet r 26695 transformants had incorporated the complete 16S rRNA gene of strain 181, while the fourth transformant contained the first part of the 16S rRNA gene of strain 26695 and the second part of strain 181. The DNA crossover in this transformant occurred after nucleotide 93 and before 127 (numbering according to 16S rrnA of H. pylori strain 26695). For each strain or transformant, only one sequence was obtained for the 16S rRNA genes, indicating that these 16S rRNA genes were identical in these strains.
Identification of 16S rRNA mutations involved in tetracycline resistance. To determine which residues of the 16S rRNA genes were responsible for tetracycline resistance in strain 181, the FIG. 2. Both 16S rRNA genes are mutated in H. pylori tetracycline resistance. rrnA-and rrnB-specific sequences were amplified using specific primers based on sequences which are found outside the two 16S rRNA genes. The rrnA-specific primers, F1 and F2, are located at position 1207020 and 1207242 (numbers corresponding to the H. pylori 26695 sequence [23] ), respectively, and the rrnB-specific primers, F3 and F4, are located at position 1510569 and 1510809, respectively. For amplification, primer R1 (located at position 1208293 and 1511828) was used in combination with one of the other primers. All primers had a length of 20 bp.
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domly selected Tet r transformants determined by E-test was 8 g/ml, which was identical to that for the Tet r donor strain 181. The only difference found between these Tet r 26695 transformants and the Tet s strain was the triple-base-pair substitution AGA 926-928 3TTC (Fig. 1) .
Both copies of 16S rRNA genes are involved in tetracycline resistance. The primers that were originally used for amplification of the 16S rRNA genes did not distinguish between the two copies present on the H. pylori chromosome (1, 23) . To assess the involvement of each copy of the 16S rRNA genes in tetracycline resistance, specific oligonucleotide primers were developed (Fig. 2) . These specific primers are based on sequences which are located approximately 350 to 600 bp outside the both 16S rRNA genes, rrnA and rrnB. This allowed amplification of rrnA-and rrnB-specific sequences. rrnA-and rrnBcontaining PCR-fragments were obtained for the Tet r strain 181, the eight 26695 transformants, and Tet s strain 26695, and their DNA sequences were determined. As expected, the rrnA and rrnB sequences were identical, where as the sequences outside the 16S rRNA genes were different. While the Tet s strain-derived fragments contained the AGA sequence in both genes, both for strain 181 and the eight 26695 transformants, the triple-base-pair substitution AGA 926-928 3TTC was found in both copies of the 16S rRNA genes. The tetracycline resistance present in these strains was always transferred together with metronidazole resistance to a Tet s strain (13) . In these Tet r strains it is not clear whether the tetracycline resistance is caused by a known metronidazole resistance mechanism, a multidrug resistance mechanism, or an unknown tetracycline resistance mechanism (13). In our Tet r H. pylori strain 181, no cross-resistance was found against metronidazole, which indicated that the molecular mechanism of tetracycline resistance in strain 181 could be different from that of these earlier-described Tet r H. pylori strains. In H. pylori strain 181 resistance to tetracycline is mediated by a single triple-base-pair substitution, AGA 926-928 3 TTC (corresponding to bp 965 to 967 of Escherichia coli 16S rRNA), present in both copies of the 16S rRNA gene. Tetracycline has one primary and multiple secondary binding sites within the 30S ribosomal subunit (3, 19) . In the primary binding site, tetracycline binds exclusively to the 3Ј-major domain of the 16S rRNA. The primary binding pocket for tetracycline is formed by the 16S rRNA residues 1054 to 1056 and 1196 to 1200 of helix 34 and residues 964 to 967 of helix 31 (numbers corresponding to E. coli 16S rRNA) (3). The residues 1054 and 1196 interact primarily with tetracycline through hydrophobic interactions, but the majority of the interaction with the drug is made through hydrogen bonds and salt bridges between tetracycline and the 16S rRNA residues (Fig. 3) (3 ). In the Tet r H. pylori strain 181, the triple-base-pair substitution AGA 926-928 3TTC is located right in the primary binding site of tetracycline. Mutations in this primary binding site are likely to affect the affinity of the drug-ribosome interaction and thus the efficacy of tetracycline as a translational inhibitor.
DISCUSSION
In E. coli, the nucleotides G 966 and C 967 are located not only in the primary binding site of tetracycline but also in a functional region of the ribosome, the P site (16, 26) . Mutations in this region may affect protein synthesis (10) , either by a change in binding of tRNA to the P site itself or by blocking the conformational change needed for the tRNA binding to the A site. In H. pylori strain 181 and the Tet r transformants of strain FIG. 3 . Schematic representation of the primary binding site of tetracycline, based on the 16S rRNA structure of Thermus thermophilus proposed by Wimberly et al. (29) . The primary binding pocket for tetracycline is formed by the 16S rRNA residues 1054 to 1056 (box A) and residues 1196 to 1200 (box B) of helix 34 and residues 964 to 967 of helix 31 (box C). The interactions between tetracycline and this pocket are formed by hydrophobic interactions, hydrogen bonds, and salt bridges (3). The triple-base-pair substitution AGA 926-928 3TTC (corresponding to bp 965 to 967 of E. coli 16S rRNA) is located in box C and is indicated by asterisks. a Data shown are the averages of three independent experiments. The isolates were considered resistant when the MICs of the tetracyclines (tetracycline, doxycycline, and minocycline), amoxicillin, clarithromycin, and metronidazole were Ն4, Ն8, Ն2, and Ն8 g/ml, respectively (5, 13 
